

The T Cell Receptor Repertoire in Psoriatic Synovitis Is Restricted and T Lymphocytes Expressing the Same TCR Are Present in Joint and Skin Lesions

LORENA BORGATO, ANTONIO PUC CETTI, RUGGERO BERI, ORAZIO CODELLA, ANTONIO FRIGO, SARA SIMEONI, MARIA LUISA PACOR, ROBERTO CORROCHER, and CLAUDIO LUNARDI

ABSTRACT. Objective. To investigate the T cell receptor (TCR) repertoire in psoriatic synovitis and to determine whether T lymphocytes in joint and skin lesions show the same V β CDR3 region.

Methods. The expression of V α and V β families was evaluated by reverse transcriptase-polymerase chain reaction. The CDR3 region of some V β families was analyzed by cloning and sequencing.

Results. We found a diverse variable β chain usage within psoriatic synovial fluid of 11 patients although some V α and V β families were more frequently expressed without evidence of clonality. Analysis of TCR in skin and synovial lesions of 3 patients showed identical CDR3 sequences, indicating that T cells bearing the same TCR are present at the 2 sites of chronic inflammation.

Conclusion. These data suggest that common or similar crossreactive antigens present in the 2 locations are responsible for the expansion of the same TCR-bearing T cells possibly already activated by a superantigen. This supports the hypothesis that both polyclonal and oligoclonal lymphocyte activation contribute to the initiation and persistence of psoriatic arthritis. (J Rheumatol 2002;29:1914-9)

Key Indexing Terms:

T CELL RECEPTOR PSORIATIC ARTHRITIS CDR3 SUPERANTIGEN

Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that occurs in 5 to 7% of patients with psoriasis¹. Its prevalence in Northern Italian patients with psoriasis has been reported to be as high as 24%².

The etiopathogenesis of PsA is still poorly understood but genetic, immunologic, and environmental factors are believed to play a central role in the induction and perpetuation of the disease, for which new subgroup classifications have been proposed³⁻⁶.

Genetic predisposition to PsA has been extensively studied and different associations with HLA class I and II genes have been reported^{4,7-14}.

A large body of evidence suggests that psoriasis is a T cell mediated autoimmune disease induced and/or exacerbated by streptococcal superantigens (SAG)¹⁵. Analysis of the T cell receptor (TCR) repertoire of T cells infiltrating skin lesions has shown an overrepresentation of V β 2, V β 5.1, V β 8, and V β 12 families¹⁶ known to be recognized by streptococcal SAG¹⁷. The sequence of the CDR3 region of the V β families preferentially expressed has given conflicting results, showing either extensive junctional diversity^{18,19} or highly conserved amino acid sequences^{20,21}, which would suggest the involvement of a conventional antigen rather than a SAG in the pathogenesis of psoriatic lesions.

T cells also play a central role in psoriatic synovitis, but only 2 studies have been reported on the TCR repertoire in psoriatic joints^{21,22}. We studied the TCR repertoire expressed in psoriatic synovitis.

We previously reported the preferential expression of some TCR V genes in rheumatoid synovitis, using a semi-quantitative polymerase chain reaction (PCR) based technique^{23,24}. In this study we used the same method to compare the expression of V α and V β gene families in paired synovial fluid and peripheral blood T cells from 11 patients with PsA. The TCR repertoire was also evaluated in the skin of 3 patients, allowing comparison between the 2 sites of chronic inflammation. We then sequenced the CDR3 region of some V β expressed more in the synovial fluid in order to analyze the presence of clonality. Finally, to evaluate whether clonally expanded T lymphocytes are involved in the pathogenesis of both the cutaneous lesions and the

From the Department of Clinical and Experimental Medicine and the Department of Medicine and Public Health, Section of Internal Medicine, University of Verona, Verona; the Department of Experimental Medicine, University of Genova; and the Giannina Gaslini Institute, Genova, Italy.

Supported by grants from the Regione Veneto and Ministero dell'Universita' e della Ricerca Scientifica e Tecnologica, n.9906242552-002 (CL), and from Ceriverona Foundation (RC).

L. Borgato, MS; R. Beri, MS; A. Frigo, MD; S. Simeoni, MD; M.L. Pacor, MD, Associate Professor; C. Lunardi, MD, Associate Professor, Department of Clinical and Experimental Medicine; R. Corrocher, MD, Full Professor of Internal Medicine; O. Codella, MD, Department of Medicine and Public Health, University of Verona; A. Puccetti, MD, Associate Professor, Department of Experimental Medicine, University of Genova and G. Gaslini Institute, Genova.

Address reprint requests to Dr. C. Lunardi, Department of Clinical and Experimental Medicine, Section of Internal Medicine, Policlinico GB Rossi, University of Verona, 37134 Verona, Italy.

E-mail: lunardi@cimib.univr.it

Submitted November 23, 2001; revision accepted March 12, 2002.

synovitis, we compared the CDR3 region of the same V β family at both sites.

MATERIALS AND METHODS

Patients. Eleven patients (9 men, 2 women) with PsA were studied. Their HLA status and duration of disease are detailed in Table 1. In 3 of the 11 patients, the synovial fluid from both knees was analyzed; one patient was studied on 3 occasions, months apart. Two other patients were studied

twice. Peripheral blood (PB) and synovial fluid (SF) samples were obtained at the same time and were used immediately to isolate mononuclear cells. In 3 cases (Patients 6, 9, and 11, Table 1) PB, SF, and skin lesions were analyzed.

Cell isolation and RNA extraction. Paired PB and SF samples were collected in preservative-free heparin (5 u/ml); SF samples were incubated with 3000 units of hyaluronidase (Sigma Pharmaceuticals, Milan, Italy) for 30 min at room temperature. Mononuclear cells were isolated by density gradient centrifugation on Ficoll (Lymphoprep, Nycomed, Oslo, Norway).

Table 1. HLA status and V genes found to be increased in the SF compared to PB of 11 patients.

Patient	Sex	Disease duration, yrs	HLA	V α	V β
1	M	9	A: 26 (10), 29 (19) B: 7, 44 (12), Cw7 DR: 7, 15 (2), 51, 53 DQ: 1, 2	5, 13, 17	—*
2	M	10	A: 30 (19) B: 16, 53; Cw4 DR: 7, 13 (6), 52, 53 DQ: 2, 3	2, 5, 7, 11	2, 3, 12, 13.1, 15
3	M	8	A: 1, 2 B: 15 (62); Cw3 DR: 2, w11, w5 DQ: w1 (w6), w3 (27)	R: 4, 5, 6, 9, 14 L: —	5.1, 8, 12, 13.1, 14, 15, 18, 20 2, 5.1, 12, 18, 20
4	M	14	A: 2, 24 (9) B: 35; Cw4 DR: 1, 11 (5), 52 DQ: 1, 7 (3)	R: — L: 6, 18	— 5.1, 11, 13.2
5	F	11	A: 1, 3 B: 35, 39 (16) C: w4, s7 DR: 1, 14 (6), 52 DQ: 1	18	10
6	F	10	A: 1, 2 B: 8, 44 (12) C: w4, w6 DR: 4, 8, 53 DQ: 3	3, 5, 7, 15, 18	2, 5.1, 8, 12, 13.1, 14, 15
7	M	4	A: 3, 11 B: 35, 39 (16) C: w4, w7 DR: 4, 8, 52 DQ: 3, 4	—	13.1, 14
8	M	3	A: 2, 24 (9) B: 39 (16), 44 (12) C: w7 DR: 1, 13 (6), 52 DQ: 1	6, 9, 11, 17	3, 5.1, 8, 15, 21
9	M	9	ND	—	5.2, 14, 15, 18
10	M	1	A: 11, 32 (19) B: 44 (12); w4; C— DR: 7, 11 (5), 52, 53 DQ: 2, 7 (3)	R: 14, 15, 16, 17 L:—	13.1, 20 —
11	M	1	A: 1, 2 B: 8, 40; w6 C: w2, w7 DR: 3, 6, 52 DQ: 1, 2	ND	2, 12, 13.1, 21

R: right knee; L: left knee; ND: not done; * —: no V families were found to be increased in the SF.

Skin biopsy was immediately frozen in liquid nitrogen and then homogenized with a small grinder. RNA was obtained from mononuclear cells and from skin following the cesium chloride-guanidinium thiocyanate method.

PCR analysis of TCR V α and V β expression. Reverse transcriptase (RT) PCR analysis was carried out as described²³. Briefly, 4 μ g total RNA was used in each RT reaction, with 50 units of avian myeloblastoma virus reverse transcriptase (Life Technologies, Milan, Italy) and 100 ng of C β or C α -specific oligonucleotide (C β : 5'-CTCTTGACCATGGCCATAAC-3'; C α : 5'-CAAGCTTTTCTCGACCAGC-3'). The reaction products were added to a master mix for PCR amplification of 22 V β and 18 V α families and of the C region. The sequences of the primers used and their relative positions in the TCR β and α cDNA have been described²³. After a 5 min denaturation step at 95°C, PCR amplification was performed at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min for a total of 30 cycles on a Perkin-Elmer thermal cycler (Perkin-Elmer, Milan, Italy). Negative controls (without cDNA added) were included for each set of experiments. Five microliters of the 50 μ l PCR amplified product were visualized as a single band on ethidium bromide stained 1% agarose gel under UV light.

Quantification of V α and V β expression. PCR products were transferred onto a nylon membrane (Hybond N+; Amersham, Buckinghamshire, UK) using a slot blot apparatus (Hybri-slot manifold; BRL, Gaithersburg, MD, USA) and hybridized with a ³²P-CTP radiolabeled cDNA. The hybridization signal was analyzed using both a beta counter (Beckman LS 1801) and a densitometer (LKB Bromma Ultrascan xL Laser Densitometer, Sweden).

The level of expression of individual V β and V α families was calculated as an expression index, which compares the expression of paired SF and PB T cells from each patient, corrected for differences in the total amount of TCR α and β mRNA between the 2 locations:

$$(V_{sf}/C_{sf}) / (V_{pb}/C_{pb}) = \text{expression index}$$

Assay reproducibility and validation of the expression index using pairs of samples of cell lines with known TCR and known number of cells have been reported²³. Since an expression index > 2 indicates a difference in cell ratio between 100:1 and 1000:1, we used an expression index > 2 as the threshold to indicate a significant increase of a particular V gene family in one compartment over the other.

Cloning and sequencing of NDJ (CDR3) region. DNA obtained from PCR amplification of V β gene families was blunt-end ligated into double stranded M13mp18 DNA and transformed into *Escherichia coli* TG2 strain. Recombinant phages were identified by screening of filter lifts that were transferred onto Hybond N membranes with a radiolabeled C β probe. Sequencing was carried out using the dideoxy chain termination method using modified T7 DNA polymerase (Sequenase; US Biochem, Cleveland, OH, USA) and run on a 6% polyacrylamide gel. Nucleotide sequences were translated to obtain the amino acid sequence of the CDR3 region in order to identify the clonotype of the TCR transcript.

RESULTS

HLA status. Table 1 shows the HLA status of the patients analyzed: DR7 was present in 3 patients; one of them (Patient 1) had multiple erosions. DR1 was present in 3 patients, all with severe arthritis, one (Patient 5) with erosions. DR4 was present in 2 patients, one (Patient 6) with an RA-like disease, and finally, DR3 was present in one patient (Patient 11, 22 yrs old), who already had erosions one year after disease onset.

TCR V α and V β genes in SF. The V α and V β families that were preferentially expressed in patients' SF are shown in Table 1: many different V α and V β families were overexpressed in the SF compared to PB. In particular, some V β

Table 2. V α and V β found to be increased in the SF compared to PB of the 3 patients analyzed in different occasions.

Patient	Time Points (mo)	V α	V β
1	0	5, 13, 17	—*
	10	2, 5, 7	—
4	0	R: —	—
	4	L: 6, 18	5.1, 11, 13.2
		R: 5, 9	3, 6, 8, 9, 13.1, 14, 15, 18, 21
	12	L: 11	13.1, 14, 18, 21
7	0	R: —	1, 5.1, 14
	19	L: 7, 9, 13, 14, 16	2, 5.1, 6, 14, 16, 17
		—	13.1, 14, 17
		—	14

* — no V families were found to be increased in the SF compared to PB.

were more frequently increased than others: V β 13.1 was increased in the SF of 6 of 11 patients; V β 15 in 5 of 11 patients; V β 2, V β 5.1, V β 12, and V β 14 in 4 of 11 patients; and V β 8 and V β 21 in 3 of 11 patients.

When 2 joints were analyzed simultaneously (Patients 3, 4, 10, Table 1), different patterns of TCR expression were found in different joints (right vs left knee); however, in Patient 3 some V β were the same. Patient 4 was analyzed 3 times and 2 other patients (Patients 1 and 7) were studied twice; as shown in Table 2, the pattern of the V families increased in SF changes during the course of the disease.

Taken together, these data indicate that different V α and V β families are expressed more in the SF of patients with PsA, and that some of the V β preferentially expressed in the SF are those reported to be recognized by streptococcal SAG (V β 2, 5.1, 8, 12, and 14). These results also imply that psoriatic synovial inflammation is a dynamic process, since the pattern of TCR repertoire may vary at different stages of the disease.

V β expression in SF and cutaneous lesions. To study the TCR repertoire expressed in cutaneous and synovial lesions, we compared the V β gene families preferentially expressed in the SF and skin lesions of 3 patients. The pattern of the TCR repertoire in perilesional skin was not different from the pattern found in matched PB samples (data not shown). On the contrary, in the lesional skin, some V β gene families were more expressed than in PB (Table 3). These findings may be related to a selective recruitment of some T lymphocytes at the site of skin and articular inflammation.

Analysis of V β CDR3 region. To determine whether the increased expression of certain V gene families in the synovial compartment is due to polyclonal activation or to expansion of a clonal subset bearing a particular TCR, we sequenced the CDR3 region of V β 2 that was more expressed in the SF and skin lesion of Patient 11, and the CDR3 region of V β 14 from SF and skin lesion of Patients 6 and 9 (Table 4). These V β families were chosen because they were pref-

Table 3. V β families found to be increased in the SF and in skin lesion of the 3 patients studied.

Patient	SF vs PB	Skin vs PB
6	2, 5.1, 8, 12, 13.1, 14, 15	2, 12, 14
9	5.2, 14, 15, 18	2, 3, 14
11	2, 12, 13.1, 21	2, 3

entially expressed in SF and cutaneous lesions and because they are recognized by streptococcal SAg.

We did not find a conserved amino acid sequence in the SF, thus excluding the presence of clonality. On the contrary, different clonotypes were found more than once in the cutaneous lesion. Surprisingly, some sequences were present in both locations, indicating that the same T lymphocytes may infiltrate different sites of inflammation.

DISCUSSION

We show that in psoriatic synovitis, there is a restricted TCR repertoire without evidence of clonal expansion, and that lymphocytes expressing the same TCR are present in joint and skin.

We found that different V α and V β genes are increased in different patients, and that the pattern of preferentially expressed V families changes during the disease course, as in rheumatoid arthritis²⁵ and in psoriatic skin lesions²⁶, implying that the process of psoriatic skin and synovium inflammation is dynamic. Many reasons may account for the findings of a different preferential V gene usage in different patients: (1) the genetic background, (2) previous systemic and local treatment, (3) the stage of the lesion due to the release of additional self-antigens and/or to epitope spreading²⁷, and (4) the low number of pathogenic T cells at the site of chronic autoaggression.

Some of the V β genes found preferentially expressed in the SF, such as V β 13.1, 2, 5.1, 8, 12, and 14, have been reported to be increased in skin lesions and are recognized

by SAg. A consequence of SAg stimulation would be an extensive β chain junctional diversity, and indeed, analysis of the CDR3 region of different V β that were increased in the SF showed no conserved sequence. These findings support the hypothesis proposed by Valdimarsson, *et al*¹⁵ and by others¹⁹ for the guttate psoriasis skin lesions, that psoriasis may be initiated or exacerbated by β -hemolytic streptococci and/or to a lesser extent by other possible pathogenic organisms such as *Staphylococcus aureus* and *Candida albicans*. Staphylococcal SAg seem to exacerbate PsA²⁸, whereas streptococci reactive T lymphocytes seem unlikely to play a role in the pathogenesis of PsA²⁹. Both host factors and immunologic triggers probably differ in the different forms of cutaneous psoriasis and in the onset of PsA.

Our findings on the TCR repertoire in psoriatic synovitis differ from previous reports^{21,22} that describe the presence of an oligoclonal population in SF. Different reasons may account for this discrepancy, such as different duration of the disease in the patients analyzed, variances in the patient population (e.g., HLA status), and methodologic differences. Also, analysis of the TCR repertoire in skin lesions has given conflicting results¹⁸⁻²¹.

The patients whose repertoire has been studied in SF and skin lesions showed the presence of multiple clonotypes in the cutaneous lesion analyzed, but not in the perilesional skin. The significance of these different T cell clones present at very low frequency (< 10%) is uncertain, although activation in an oligoclonal manner following antigen recognition is the only possible explanation. Remarkably, when the CDR3 sequences of different V β in the SF and skin were compared, we found that some clonotypes were the same in both locations. The evidence that T cells bearing the same receptor are present at 2 different sites of inflammation are not in contrast with a report by Pitzalis, *et al*³⁰, who described the lack of the adhesion molecule cutaneous lymphocyte antigen (CLA) in synovium-infiltrating lymphocytes. The clonotypes identified in skin and

Table 4. Frequency and CDR3 sequence of the V β clonotypes found in the SF and skin lesions of Patients 6, 9, and 11. The amino acid sequence is shown in a single letter code. The last 4 amino acids of the V β segment are shown, followed by the NDN region sequence and the first 3 amino acids of the J region.

Patient	Frequency SF	Frequency Skin	V β	NDN	J
6	1/21	3/35	V β 14 CASS	LSSGG	YGY 1.2
	1/21	4/35	V β 14 CASS	GE	QET 2.5
	1/21	1/35	V β 14 CASS	DRASYDE	YF 2.3
9	1/15	1/28	V β 14 CASS	LISY	NEQ 2.1
	1/15	3/28	V β 14 CASS	TLGGVP	NYG 1.2
	1/15	2/28	V β 14 CAS	RNVAGGA	YEQ 2.7
	1/15	1/28	V β 14 CASS	LGC	NYG 1.2
11	1/35	1/44	V β 2 CSA	RQGD	TEA 1.1
	1/35	2/44	V β 2 CS	EGSGRSK	YNE 2.1
	0/35	3/44	V β 2 CSA	EGGK	NEO 2.1
	0/35	2/44	V β 2 CS	YEPGLK	QET 2.5
	0/35	2/44	V β 2 CSA	ETGKD	EQF 2.1
	0/35	2/44	V β 2 CSA	PGQQK	QET 2.5

synovium may be either CLA negative, since a high percentage of skin-infiltrating lymphocytes lack the CLA antigen, or may be divergent with regard to this marker, the acquisition of which seems to be necessary for homing to skin but not synovium. Similarly, the finding by the same group of a preferential localization of CD1 positive antigen-presenting cells to the skin but not to the joint seems to be a general property of these cells rather than a disease-specific phenomenon for PsA³¹.

Molecular mimicry is a possible mechanism that helps explain autoaggression following infection, and indeed extensive sequence homology between streptococcal M proteins and human 50 kDa type I keratin has been reported³². Moreover, monoclonal antibodies that crossreact with group A streptococci and normal and psoriatic human skin³³, as well as circulating T cells from patients with psoriasis responsive to streptococcal M peptides sharing homology with human epidermal keratins, have been described^{32,34}. The pathological significance of such cross-reactivity between bacterial antigens and autoantigens is not fully understood. However, autoimmune responses can be triggered by exogenous protein epitopes with crucial amino acids homologous to self-proteins. Indeed, we and others have recently reported that IgG from sera of patients with PsA recognize a phylogenetically highly conserved glycine-rich cell wall protein (GRP) that shares homology with autoantigens such as keratin, collagen II, and a viral antigen such as EBNA-I³⁵. Moreover anti-GRP-specific T cell clones have been derived from PB of patients with PsA.

Our findings of conserved sequences of the TCR V β hypervariable region CDR3 in SF and skin lesions of the same patient suggest an immune response towards cross-reactive antigens in the 2 sites possibly triggered by exogenous agents via a molecular mimicry mechanism^{35,36}. Another possibility is that, depending on the genetic background and the nature of the triggering agent, SAg may activate particular V β -expressing autoreactive T cells subsequently expanded by a local antigen driven process, as proposed for rheumatoid arthritis^{37,38}.

Our results are in accord with evidence that both polyclonal and oligoclonal lymphocyte activation contribute to the initiation and persistence of psoriasis³⁹, and suggest that similar or identical autoantigens are recognized at the 2 sites of chronic inflammation.

REFERENCES

- Espinoza LR, Cuellar ML, Silveira LH. Psoriatic arthritis. *Curr Opin Rheumatol* 1992;4:470-8.
- Salvarani C, Lo Scocco G, Macchioni P, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. *J Rheumatol* 1995;22:1499-503.
- Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis: an analysis of 220 patients. *Q J Med* 1987;62:127-41.
- Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. *Br J Rheumatol* 1991;30:245-50.
- Halliwell P, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of osteo-articular manifestation of psoriasis. *Br J Rheumatol* 1991;30:339-45.
- Veale D, Rogers S, Fitzgerald O. Classification of clinical subset in psoriatic arthritis. *Br J Rheumatol* 1994;33:133-8.
- Murray C, Mann DL, Gerber LN, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. *J Clin Invest* 1980;66:670-5.
- Fournie B, Granel J, Heraud A, et al. HLA-B et rhumatisme psoriasique: étude de 193 cas. *Rev Rhum Mal Osteoartic* 1991;58:269-73.
- Espinoza LR, Vasey FB, Oh JH, Wilkinson R, Osterland CK. Association between HLA-Bw38 and peripheral psoriatic arthritis. *Arthritis Rheum* 1978;21:72-5.
- Salvarani C, Macchioni PL, Zizzi F, et al. Clinical subgroups and HLA antigen in Italian patients with psoriatic arthritis. *Clin Exp Rheumatol* 1989;7:391-6.
- Sakkas LI, Loqueman N, Bird H, Vaughan RW, Welsh KI, Panayi GS. HLA class II and T cell receptor gene polymorphisms in psoriatic arthritis and psoriasis. *J Rheumatol* 1990;17:1487-90.
- McMenemy A, Reveille J. MCH-class II heterogeneity by restriction fragment length polymorphism and polymerase chain reaction in psoriatic arthritis [abstract]. *Arthritis Rheum* 1990;33 Suppl:S68.
- Gonzalez S, Martinez-Borra J, Torre-Alonso JC, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. *Arthritis Rheum* 1999;42:1010-6.
- Gonzalez S, Brautbar C, Martinez-Borra J, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. *Hum Immunol* 2001;62:632-8.
- Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? *Immunol Today* 1995;16:145-9.
- Lewis HM, Baker BS, Bokth S, et al. Restricted T-cell receptor V beta gene usage in the skin of patients with guttate and chronic plaque psoriasis. *Br J Dermatol* 1993;129:514-20.
- Abe J, Forrester J, Nakahara T, Lafferty JA, Kotzin BL, Leung OY. Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. *J Immunol* 1991;146:3747-50.
- Moss P, Charmley P, Mulvihill E, et al. The repertoire of T cell antigen receptor beta-chain variable regions associated with psoriasis vulgaris. *J Invest Dermatol* 1997;109:14-9.
- Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. *J Clin Invest* 1995;96:2106-12.
- Chang JC, Smith LR, Froning KJ, et al. CD8+ T cells in psoriatic lesions preferentially use T cell receptors V β 3 and/or V β 13.1 genes. *Proc Natl Acad Sci USA* 1994;91:9282-6.
- Tassioulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. *Hum Immunol* 1999;60:479-91.
- Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. *J Immunol* 2001;166:2878-86.
- Lunardi C, Marguerie C, So AK. An altered repertoire of T-cell receptor V gene expression by rheumatoid synovial fluid T-lymphocytes. *Clin Exp Immunol* 1992;90:440-6.
- Borgato L, Beri R, Biasi D, et al. Analysis of the T cell receptor repertoire in rheumatoid arthritis. *Clin Exp Rheumatol* 1997;15:475-9.

25. Khazei HA, Lunardi C, So AK. CD4 T cells in the rheumatoid joint are oligoclonally activated and change during the course of disease. *Ann Rheum Dis* 1995;54:314-7.
26. Vekony MA, Holder JE, Lee AJ, Harrocks C, Eperon IC, Camp RD. Selective amplification of T-cell receptor variable region species is demonstrable but not essential in early lesions of psoriasis vulgaris: analysis by anchored polymerase chain reaction and hypervariable region size spectratyping. *J Invest Dermatol* 1997;109:5-13.
27. Lehmann PV, Sercarz EE, Forethuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. *Immunol Today* 1993;14:203-8.
28. Thomssen H, Hoffmann B, Schank M, Elewaut D, Meyer zum Buschenfelde KH, Marker-Hermann E. There is no specific disease-specific role for streptococci-responsive synovial T lymphocytes in the pathogenesis of psoriatic arthritis. *Med Microbiol Immunol* 2000;188:203-7.
29. Yamamoto T, Katayama I, Nishioka K. Peripheral blood mononuclear cell proliferative response against staphylococcal superantigens in patients with psoriasis arthropathy. *Eur J Dermatol* 1999;9:17-21.
30. Pitzalis C, Cauli A, Pipitone N, et al. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. *Arthritis Rheum* 1996;39:137-45.
31. Cauli A, Pitzalis C, Gianni G, Awad M, Panayi GS. CD1 expression in psoriatic and rheumatic arthritis. *Rheumatology* 2000;39:666-73.
32. Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M, Good MF, Valdimarsson H, Jonsdottir I. Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. *Scand J Immunol* 1997;45:688-97.
33. Swerlick RA, Cunningham MW, Hall NK. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. *J Invest Dermatol* 1986;87:367-71.
34. Baker BS, Bokth S, Powles A, et al. Group A streptococcal antigen-specific T lymphocytes in guttate psoriatic lesions. *Br J Dermatol* 1993;128:493-9.
35. Lunardi C, Nanni L, Tiso M, et al. Glycine rich cell wall proteins act as specific antigen targets in autoimmune and allergic disorders. *Int Immunol* 2000;12:647-57.
36. Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. *Nat Med* 2000;10:1183-6.
37. Paliard X, West SG, Lafferty JA, et al. Evidence for the effects of a superantigen in rheumatoid arthritis. *Science* 1991;253:325-9.
38. VanderBorghet A, Genzens P, Vandevyver C, Rans J, Stinissen P. Skewed T-cell receptor variable gene usage in the synovium of early and chronic rheumatoid arthritis patients and persistence of clonally expanded T cells in a chronic patient. *Rheumatology* 2000;39:1189-201.
39. Norris DA, Travers JB, Leung DY. Lymphocyte activation in the pathogenesis of psoriasis. *J Invest Dermatol* 1997;109:1-3.